As per the report published by Fior Markets,the global erythropoietin drugs market is expected to grow from USD 7.73 Billion in 2017 to USD 18.67 Billion by 2025, at a CAGR of 11.65% during the forecast period from 2018-2025.North America region led the global erythropoietin drugs market with a 44.26% share of market revenue in 2017.
“Erythropoietin Drugs Market by Drug Class (Biologics, Biosimilars), Product (Epoetin Alpha, Epoetin Beta, Others), Application, Regions”,and Global Forecast 2018-2025
DOWNLOAD FREE SAMPLE REPORT:https://www.fiormarkets.com/report-detail/386010/request-sample
Major players in the global erythropoietin drugsmarket areJohnson & Johnson, Celltrion, Inc.,Teva Pharmaceutical Industries Ltd., Pfizer Inc., Amgen, Inc., AstraZeneca, Sandoz GmbH, F. Hoffmann-La Roche Ltd., LG Life Sciences Ltd., Biocon Limited, Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd, HospiraInc, Ranbaxy Laboratories Ltd., Merck Pharmaceuticals, InSight Biopharmaceuticals, BiotechnicaPharma Global, and among others. Major pharmaceuticals firms are heavily investing on the development of novel erythropoietin drugs. For instance Molecular Health in 2015, announced that it has been granted a patent in Europe entitled “Tissue Protective Erythropoietin Receptor”. This latest patent supports Molecular Health’s discovery that EPHB4 is a novel receptor for Erythropoietin (EPO). EPHB4
Drug class segment is divided into biologics and biosimilars. On account of patent protection, widespread use of biologics in the treatment of chronic kidney diseases, the biologics erythropoietin drugs segment emerged as the leader with a 73.69% share of market revenue in 2017. Biosimilars segment is anticipated to grow at an increased CAGR of 13.58% over the forecast period. Growing investments onresearch and developmentofbiosimilars, robust product pipeline andrise in collaborations between hospitals and manufactures for the adoption of erythropoietinbiosimilars are some of the factors that areexpected to drive the growth of the biosimilar segment. Product is segmented into epoetin alpha, epoetin beta, darbepoetin alpha and others. Due to being the first US FDA approved biologic erythropoietin drug that is available for the treatment of anemia caused by the chemotherapy, HIV AIDS, chronic kidney disease and other similar diseases Epotin alpha product segment emerged as the largest with a 39.48% share of revenue in 2017. On account of its improved efficacy and longer shelf life, the Epoetin beta segment also accounted for a significant share of global erythropoietin drugs market in 2017.Application segment is categorized into cancer, hematology, renal disease, neurology and others. Factors such as increasing worldwide prevalence of chronic renal diseases as well as availability of specifically developed drugs such as Epogen led renal disease segment to emerge as a dominant application segment with a 41.38% share of revenue in 2017. On account of widespread utilization of erythropoietin drugs for the treatment of the cancer patients undergoing chemotherapy, the cancer segment is anticipated to grow at an accelerated CAGR of 13.97% over the forecasted period.
BROWSE COMPLETE REPORT AND TABLE OF CONTENTS:https://www.fiormarkets.com/report/erythropoietin-drugs-market-by-drug-class-biologics-biosimilars-386010.html
Even though increasing prevalence of chronic kidney disease, HIV AIDS and anemia diseases and rising use of biosimilar erythropoietin are driving the global erythropoietin drugs market. High cost erythropoietin drugs andpresence of side effects are the factors that are anticipated to restrain the market growth.
Customization of the Report:This report can be customized to meet the client’s requirements. Please connect with our sales team (firstname.lastname@example.org), who will ensure that you get a report that suits your needs.